检测原发性肝细胞癌HBsAg阳性患者的HBV DNA和抗原

StephenW

Clin Res Hepatol Gastroenterol. 2017 Mar 9. pii: S2210-7401(17)30044-X. doi: 10.1016/j.clinre.2017.01.009. [Epub ahead of print]
Detection of HBV DNA and antigens in HBsAg-positive patients with primary hepatocellular carcinoma.Fu S1, Li N2, Zhou PC1, Huang Y1, Zhou RR3, Fan XG4.
Author information
1Department of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan Province, Xiangya Hospital, Central South University, PO Box 410008, Changsha, China.2Department of Blood Transfusion, Xiangya Hospital, Central South University, Changsha, China.3Department of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan Province, Xiangya Hospital, Central South University, PO Box 410008, Changsha, China. Electronic address: [email protected].4Department of Infectious Diseases, Key Laboratory of Viral Hepatitis of Hunan Province, Xiangya Hospital, Central South University, PO Box 410008, Changsha, China. Electronic address: [email protected].

AbstractBACKGROUND: Hepatitis B virus (HBV) markers include HBV deoxyribonucleic acid (DNA) and HBV antigens. The former involves HBV covalently closed circular DNA (cccDNA) as well as total HBV DNA, whereas the latter involves HBsAg, HBcAg, and HBx.
METHODS: Samples of tumor and adjacent non-tumor liver tissue were collected from 28 HBV-associated HCC patients. Intrahepatic total HBV DNA and cccDNA were measured using the real-time PCR Taqman assay. HBV antigens in hepatocytes were detected using immunohistochemical staining. Intrahepatic levels of total HBV DNA or cccDNA in HCC patients with different intrahepatic HBV antigen expression patterns were compared, and the correlation between serum HBV DNA and intrahepatic HBV DNA was analyzed.
RESULTS: No significant differences in intrahepatic cccDNA levels were observed between tumor and non-tumor liver tissue (median -3.00 vs. -2.30 log copies/cell, P=0.298). However, the tumor tissue had significantly higher levels of total HBV DNA (median -0.60 vs. -1.24 log copies/cell, P=0.045) but significantly lower proportion of intrahepatic HBV DNA in the form of cccDNA (median 0.25% vs. 4%, P=0.023) than the corresponding values in the non-tumor tissue. Also, HBV antigen levels were lower in the tumor tissue than in the non-tumor tissue. Analysis of the correlation between serum HBV DNA and intrahepatic HBV DNA indicated that the viral status in the tumor tissue was more complicated in HBV-HCC patients-the detected serum HBV DNA failed to accurately reflect intrahepatic viral load.
CONCLUSION: HBV DNA may play an important role in hepatocarcinogenesis, and cccDNA was not the predominant form of HBV DNA in the tumor tissue.


Copyright © 2017 Elsevier Masson SAS. All rights reserved.



PMID:28286056DOI:10.1016/j.clinre.2017.01.009

• 
  


• 
  

StephenW

Clin Res Hepatol Gastroenterol。 2017年3月9日。pii：S2210-7401（17）30044-X。 doi：10.1016 / j.clinre.2017.01.009。 [打印前的电子版]
检测原发性肝细胞癌HBsAg阳性患者的HBV DNA和抗原。
Fu S1，Li N2，Zhou PC1，Huang Y1，Zhou RR3，Fan XG4。
作者信息

1
    中南大学湘雅医院传染病传染病重点实验室，湖南省病毒性肝炎重点实验室，邮政编码410008，长沙。
2
    中南大学湘雅医院输血系，中国长沙。
3
    中南大学湘雅医院传染病传染病重点实验室，湖南省病毒性肝炎重点实验室，邮政编码410008，长沙。电子地址：[email protected]。
4
    中南大学湘雅医院传染病传染病重点实验室，湖南省病毒性肝炎重点实验室，邮政编码410008，长沙。电子地址：[email protected]。

抽象
背景：

乙型肝炎病毒（HBV）标记包括HBV脱氧核糖核酸（DNA）和HBV抗原。前者涉及HBV共价闭合环状DNA（cccDNA）以及总HBV DNA，而后者涉及HBsAg，HBcAg和HBx。
方法：

从28个HBV相关的HCC患者中收集肿瘤和相邻非肿瘤肝组织的样品。使用实时PCR Taqman测定法测量肝内总HBV DNA和cccDNA。使用免疫组织化学染色检测肝细胞中的HBV抗原。比较不同肝内HBV抗原表达模式的HCC患者肝内HBV DNA或cccDNA的肝内水平，分析血清HBV DNA与肝内HBV DNA的相关性。
结果：

在肿瘤和非肿瘤肝组织之间没有观察到肝内cccDNA水平的显着差异（中值-3.00对-2.30log拷贝/细胞，P = 0.298）。然而，肿瘤组织具有显着更高的总HBV DNA水平（中值-0.60对-1.24log拷贝/细胞，P = 0.045），但是以cccDNA的形式显着降低肝内HBV DNA的比例（中值0.25％对4 ％，P = 0.023）比非肿瘤组织中的对应值。此外，在肿瘤组织中的HBV抗原水平比在非肿瘤组织中低。血清HBV DNA和肝内HBV DNA之间的相关性分析表明，在HBV-HCC患者中，肿瘤组织中的病毒状态更复杂 - 检测到的血清HBV DNA不能准确反映肝内病毒载量。
结论：

HBV DNA可能在肝癌发生中起重要作用，cccDNA不是肿瘤组织中HBV DNA的主要形式。

版权所有©2017 Elsevier Masson SAS。版权所有。

PMID：
    28286056
DOI：
    10.1016 / j.clinre.2017.01.009